Connor Clark & Lunn Investment Management Ltd. Has $1.77 Million Holdings in Aveanna Healthcare Holdings Inc. $AVAH

Key Points

• Connor Clark & Lunn Investment Management Ltd. increased its stake in Aveanna Healthcare Holdings Inc. by 71.1%, acquiring a total of 326,144 shares valued at approximately $1.77 million.
• Aveanna Healthcare currently has a market cap of $1.48 billion, with shares trading between a 1-year low of $3.67 and a 1-year high of $7.61.
• Several analysts have upgraded their ratings on Aveanna Healthcare, with target prices ranging from $5.00 to $9.00, indicating mixed sentiment in the market.

Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH - Free Report) by 71.1% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 326,144 shares of the company's stock after acquiring an additional 135,574 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 0.17% of Aveanna Healthcare worth $1,768,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in AVAH. BNP Paribas Financial Markets bought a new stake in Aveanna Healthcare during the 4th quarter valued at approximately $35,000. Tower Research Capital LLC TRC boosted its stake in Aveanna Healthcare by 662.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,889 shares of the company's stock valued at $36,000 after purchasing an additional 6,854 shares during the period. Sagespring Wealth Partners LLC bought a new stake in Aveanna Healthcare during the 4th quarter valued at approximately $57,000. Walleye Capital LLC bought a new stake in Aveanna Healthcare during the 4th quarter valued at approximately $64,000. Finally, ProShare Advisors LLC bought a new stake in Aveanna Healthcare during the 4th quarter valued at approximately $67,000. Institutional investors own 87.96% of the company's stock.

Insider Buying and Selling

In other Aveanna Healthcare news, major shareholder Paul R. Vigano sold 750,000 shares of the firm's stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $5.20, for a total value of $3,900,000.00. Following the completion of the sale, the insider owned 28,890,756 shares in the company, valued at approximately $150,231,931.20. This trade represents a 2.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Deborah Stewart sold 15,457 shares of the firm's stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $5.56, for a total value of $85,940.92. Following the completion of the sale, the chief accounting officer owned 285,396 shares of the company's stock, valued at $1,586,801.76. This represents a 5.14% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,295,145 shares of company stock worth $11,941,141. 7.80% of the stock is currently owned by corporate insiders.

Aveanna Healthcare Stock Down 2.2%

Shares of AVAH stock traded down $0.16 during mid-day trading on Thursday, reaching $7.04. The stock had a trading volume of 983,525 shares, compared to its average volume of 1,709,008. The firm's 50 day simple moving average is $4.92 and its 200 day simple moving average is $4.94. Aveanna Healthcare Holdings Inc. has a one year low of $3.67 and a one year high of $7.61. The firm has a market cap of $1.47 billion, a PE ratio of 88.00 and a beta of 1.95.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on AVAH. Jefferies Financial Group upgraded Aveanna Healthcare from a "hold" rating to a "buy" rating and decreased their target price for the company from $6.25 to $6.00 in a research note on Monday, July 21st. Truist Financial decreased their target price on Aveanna Healthcare from $6.00 to $5.00 and set a "hold" rating for the company in a research note on Wednesday, July 16th. UBS Group upgraded Aveanna Healthcare from a "sell" rating to a "neutral" rating and increased their target price for the company from $6.75 to $8.00 in a research note on Tuesday. Wall Street Zen upgraded Aveanna Healthcare from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Finally, Barclays upgraded Aveanna Healthcare from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $5.50 to $9.50 in a research note on Tuesday. Three analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Aveanna Healthcare currently has an average rating of "Moderate Buy" and a consensus price target of $7.50.

Aveanna Healthcare Profile

Aveanna Healthcare Holdings Inc, a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities.